Glimepiride CAS NO.93479-97-1

Glimepiride is the third generation sulfonylurea antidiabetic drug lasting effect, its fall blood sugar function is the main mechanism of the stimulus islet beta cells secrete insulin, some improve surrounding tissues to insulin sensitivity. This product with the speed of the insulin receptor and dissociation glyburide for fast, less cause heavier hypoglycemia. Its mechanism is through and sulfonyl urea receptors on the surface of the pancreatic beta cells (relative molecular mass of 6.5 x 104 protein), the receptor and ATP sensitive K + (KATP) channel phase coupling, pushing the KATP channel close, cause cell membrane depolarization, makes the open voltage dependent calcium channel, Ga2 + internal flow and lead to the release of insulin, and inhibit the synthesis of liver glucose. Recent research has shown that different sulfonyl urea coal medicine is different from the affinity of KATP. The following order: glibenclamide = Glenn beauty urea > tolbutamide > sulfonyl chloride propyl urea. In addition, Glenn beauty urea can increase by non-insulin-dependent heart glucose uptake, it could be a glucose transporter factor 1, 4 caused by two kinds of protein expression is increased. Due to Glenn beauty of urea to cardiovascular KATP channels in the weaker than Glenn wave urea, gliclazide pass column pyrazine. Cardiovascular adverse reaction is very few.